• First Ascent Biomedical's xDRIVE Drug Prediction Platform, showing 83% improvement in treatment outcomes, receives funding from Florida Cancer Innovation Fund to expand personalized cancer care access.
• The AI-powered platform combines DNA/RNA sequencing, drug sensitivity testing, and machine learning to identify optimal treatments for cancer recurrence, with notable success in pediatric oncology.
• The grant will support expanding treatment access to rural and minority communities in Florida, while advancing FDA Breakthrough Device Designation and insurance coverage approvals.